XML 42 R23.htm IDEA: XBRL DOCUMENT
v3.20.2

Segment, Geographic and Other Revenue Information | 6 Months Ended
--- | ---
Jun. 28, 2020
Segment Reporting [Abstract] |
Segment, Geographic and Other Revenue Information | Segment, Geographic and Other Revenue Information A. Segment Information At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of three distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019, Pfizer’s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn is, and through July 31, 2019 Consumer Healthcare was, responsible for its own R&D activities while Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented. For additional information, see Notes to Consolidated Financial Statements—Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, and Note 2. Operating Segments
Some additional information about our Biopharma and Upjohn business segments follows:
| Pfizer Biopharmaceuticals Group |  |
Biopharma is a science-based innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. Each business unit is committed to delivering breakthroughs that change patients’ lives. |  | Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.
Select products include: - Ibrance - Eliquis - Prevnar 13/Prevenar 13 - Xeljanz - Enbrel (outside the U.S. and Canada) - Vyndaqel/Vyndamax - Chantix/Champix - Xtandi - Sutent |  | Select products include: - Lipitor - Lyrica - Norvasc - Celebrex - Viagra - Certain generic medicines
Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:
• | WRDM––the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines.
• | GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.
• | Other––the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.
• | Corporate and Other Unallocated––the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture.
• | Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities) that
are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a Total Company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $178 billion as of June 28, 2020 and $167 billion as of December 31, 2019. Selected Income Statement Information
The following table provides selected income statement information by reportable segment:
|  | Three Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Reportable Segments: |  |  |  |  |  |  |  |
Biopharma |  | $ | 9,795 |  |  | $ | 9,432 |  |  | $ | 6,650 |  |  | $ | 6,071 |
Upjohn |  | 2,006 |  |  | 2,970 |  |  | 1,168 |  |  | 1,973 |
Total reportable segments |  | 11,801 |  |  | 12,402 |  |  | 7,818 |  |  | 8,044 |
Other business activities |  | — |  |  | 862 |  |  | (1,530 | ) |  | (1,193 | )
Reconciling Items: |  |  |  |  |  |  |  |  |  |
Corporate and other unallocated |  | — |  |  | — |  |  | (1,136 | ) |  | (1,399 | )
Purchase accounting adjustments |  | — |  |  | — |  |  | (910 | ) |  | (1,178 | )
Acquisition-related costs |  | — |  |  | — |  |  | (21 | ) |  | 176 |
Certain significant items(b) |  | — |  |  | — |  |  | (268 | ) |  | (309 | )
|  | $ | 11,801 |  |  | $ | 13,264 |  |  | $ | 3,953 |  |  | $ | 4,141 |
|  | Six Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Reportable Segments: |  |  |  |  |  |  |  |
Biopharma |  | $ | 19,802 |  |  | $ | 18,477 |  |  | $ | 13,379 |  |  | $ | 11,954 |
Upjohn |  | 4,027 |  |  | 6,184 |  |  | 2,359 |  |  | 4,251 |
Total reportable segments |  | 23,829 |  |  | 24,661 |  |  | 15,738 |  |  | 16,206 |
Other business activities |  | — |  |  | 1,721 |  |  | (3,019 | ) |  | (2,306 | )
Reconciling Items: |  |  |  |  |  |  |  |
Corporate and other unallocated |  | — |  |  | — |  |  | (2,245 | ) |  | (2,676 | )
Purchase accounting adjustments |  | — |  |  | — |  |  | (1,722 | ) |  | (2,217 | )
Acquisition-related costs |  | — |  |  | — |  |  | (34 | ) |  | 148 |
Certain significant items(b) |  | — |  |  | — |  |  | (879 | ) |  | (691 | )
|  | $ | 23,829 |  |  | $ | 26,382 |  |  | $ | 7,838 |  |  | $ | 8,463 |
(a) | Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019, and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4.
(b) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information
The following table provides revenues by geographic area:
|  | Three Months Ended |  | Six Months Ended
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | % Change |  |  | June 28, 2020 |  |  | June 30, 2019 |  |  | % Change |
United States |  | $ | 5,402 |  |  | $ | 6,335 |  |  | (15 | ) |  | $ | 11,053 |  |  | $ | 12,510 |  |  | (12 | )
Developed Europe(a) |  | 2,088 |  |  | 2,228 |  |  | (6 | ) |  | 4,009 |  |  | 4,315 |  |  | (7 | )
Developed Rest of World(b) |  | 1,552 |  |  | 1,639 |  |  | (5 | ) |  | 3,008 |  |  | 3,174 |  |  | (5 | )
Emerging Markets(c) |  | 2,759 |  |  | 3,062 |  |  | (10 | ) |  | 5,759 |  |  | 6,383 |  |  | (10 | )
Revenues |  | $ | 11,801 |  |  | $ | 13,264 |  |  | (11 | ) |  | $ | 23,829 |  |  | $ | 26,382 |  |  | (10 | )
(a) | Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the second quarter of 2020 and $1.8 billion in the second quarter of 2019, and were $3.2 billion in the first six months of 2020 and $3.5 billion in the first six months of 2019.
(b) | Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
(c) | Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
C. Other Revenue Information Significant Product Revenues The following table provides detailed revenue information for several of our major products:
(MILLIONS OF DOLLARS) |  |  |  | Three Months Ended |  | Six Months Ended
PRODUCT |  | PRIMARY INDICATION OR CLASS |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
TOTAL REVENUES |  |  |  | $ | 11,801 |  |  | $ | 13,264 |  |  | $ | 23,829 |  |  | $ | 26,382 |
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) |  | $ | 9,795 |  |  | $ | 9,432 |  |  | $ | 19,802 |  |  | $ | 18,477 |
Internal Medicine(a) |  |  |  | $ | 2,279 |  |  | $ | 2,243 |  |  | $ | 4,610 |  |  | $ | 4,380 |
Eliquis alliance revenues and direct sales |  | Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism |  | 1,272 |  |  | 1,085 |  |  | 2,572 |  |  | 2,096 |
Chantix/Champix |  | An aid to smoking cessation treatment in adults 18 years of age or older |  | 235 |  |  | 276 |  |  | 505 |  |  | 549 |
Premarin family |  | Symptoms of menopause |  | 152 |  |  | 193 |  |  | 304 |  |  | 361 |
BMP2 |  | Development of bone and cartilage |  | 57 |  |  | 79 |  |  | 127 |  |  | 145 |
Toviaz |  | Overactive bladder |  | 64 |  |  | 65 |  |  | 124 |  |  | 125 |
All other Internal Medicine |  | Various |  | 498 |  |  | 544 |  |  | 978 |  |  | 1,103 |
Oncology |  |  |  | $ | 2,647 |  |  | $ | 2,236 |  |  | $ | 5,082 |  |  | $ | 4,198 |
Ibrance |  | Metastatic breast cancer |  | 1,349 |  |  | 1,261 |  |  | 2,598 |  |  | 2,394 |
Xtandi alliance revenues |  | Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer |  | 266 |  |  | 201 |  |  | 475 |  |  | 369 |
Sutent |  | Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor |  | 209 |  |  | 248 |  |  | 414 |  |  | 480 |
Inlyta |  | Advanced RCC |  | 195 |  |  | 104 |  |  | 364 |  |  | 177 |
Xalkori |  | ALK-positive and ROS1-positive advanced NSCLC |  | 138 |  |  | 133 |  |  | 287 |  |  | 255 |
Bosulif |  | Philadelphia chromosome–positive chronic myelogenous leukemia |  | 113 |  |  | 97 |  |  | 213 |  |  | 177 |
Retacrit(b) |  | Anemia |  | 87 |  |  | 51 |  |  | 176 |  |  | 82 |
Braftovi |  | In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAF V600E-mutant metastatic colorectal cancer after prior therapy |  | 36 |  |  | — |  |  | 74 |  |  | — |
Mektovi |  | In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation |  | 32 |  |  | — |  |  | 69 |  |  | — |
All other Oncology |  | Various |  | 221 |  |  | 140 |  |  | 412 |  |  | 262 |
Hospital(a), (c) |  |  |  | $ | 1,794 |  |  | $ | 1,838 |  |  | $ | 3,807 |  |  | $ | 3,665 |
Sulperazon |  | Bacterial infections |  | 102 |  |  | 165 |  |  | 289 |  |  | 342 |
Medrol |  | Anti-inflammatory glucocorticoid |  | 78 |  |  | 120 |  |  | 207 |  |  | 240 |
Zithromax |  | Bacterial infections |  | 55 |  |  | 73 |  |  | 193 |  |  | 177 |
Precedex |  | Sedation agent in surgery or intensive care |  | 114 |  |  | 40 |  |  | 156 |  |  | 80 |
Vfend |  | Fungal infections |  | 75 |  |  | 94 |  |  | 149 |  |  | 178 |
Panzyga |  | Primary humoral immunodeficiency |  | 63 |  |  | 44 |  |  | 136 |  |  | 61 |
(MILLIONS OF DOLLARS) |  |  |  | Three Months Ended |  | Six Months Ended
PRODUCT |  | PRIMARY INDICATION OR CLASS |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Zyvox |  | Bacterial infections |  | 55 |  |  | 71 |  |  | 125 |  |  | 134 |
Fragmin |  | Treatment/prevention of venous thromboembolism |  | 58 |  |  | 63 |  |  | 118 |  |  | 123 |
Pfizer CentreOne(d) |  | Various |  | 224 |  |  | 204 |  |  | 376 |  |  | 380 |
All other Anti-infectives |  | Various |  | 367 |  |  | 420 |  |  | 811 |  |  | 825 |
All other Hospital(c) |  | Various |  | 603 |  |  | 544 |  |  | 1,245 |  |  | 1,124 |
Vaccines |  |  |  | $ | 1,247 |  |  | $ | 1,375 |  |  | $ | 2,857 |  |  | $ | 2,988 |
Prevnar 13/Prevenar 13 |  | Pneumococcal disease |  | 1,116 |  |  | 1,179 |  |  | 2,566 |  |  | 2,665 |
Nimenrix |  | Meningococcal disease |  | 56 |  |  | 58 |  |  | 130 |  |  | 107 |
All other Vaccines |  | Various |  | 75 |  |  | 138 |  |  | 161 |  |  | 215 |
Inflammation & Immunology (I&I) |  | $ | 1,149 |  |  | $ | 1,219 |  |  | $ | 2,127 |  |  | $ | 2,256 |
Xeljanz |  | RA, PsA, UC |  | 635 |  |  | 613 |  |  | 1,086 |  |  | 1,036 |
Enbrel (Outside the U.S. and Canada) |  | RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis |  | 337 |  |  | 420 |  |  | 684 |  |  | 871 |
Inflectra/Remsima(b) |  | Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis |  | 150 |  |  | 153 |  |  | 308 |  |  | 291 |
All other I&I |  | Various |  | 26 |  |  | 34 |  |  | 48 |  |  | 59 |
Rare Disease |  |  |  | $ | 681 |  |  | $ | 521 |  |  | $ | 1,319 |  |  | $ | 991 |
Vyndaqel/Vyndamax |  | ATTR-cardiomyopathy and polyneuropathy |  | 277 |  |  | 63 |  |  | 508 |  |  | 104 |
BeneFIX |  | Hemophilia B |  | 109 |  |  | 121 |  |  | 230 |  |  | 247 |
Genotropin |  | Replacement of human growth hormone |  | 106 |  |  | 125 |  |  | 209 |  |  | 232 |
Refacto AF/Xyntha |  | Hemophilia A |  | 91 |  |  | 108 |  |  | 181 |  |  | 214 |
Somavert |  | Acromegaly |  | 67 |  |  | 68 |  |  | 131 |  |  | 128 |
All other Rare Disease |  | Various |  | 31 |  |  | 35 |  |  | 61 |  |  | 66 |
UPJOHN(a) |  |  |  | $ | 2,006 |  |  | $ | 2,970 |  |  | $ | 4,027 |  |  | $ | 6,184 |
Lipitor |  | Reduction of LDL cholesterol |  | 431 |  |  | 407 |  |  | 836 |  |  | 1,029 |
Lyrica |  | Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury |  | 349 |  |  | 1,175 |  |  | 706 |  |  | 2,362 |
Norvasc |  | Hypertension |  | 222 |  |  | 216 |  |  | 419 |  |  | 516 |
Celebrex |  | Arthritis pain and inflammation, acute pain |  | 139 |  |  | 174 |  |  | 295 |  |  | 347 |
Viagra |  | Erectile dysfunction |  | 94 |  |  | 114 |  |  | 222 |  |  | 259 |
Effexor |  | Depression and certain anxiety disorders |  | 86 |  |  | 86 |  |  | 163 |  |  | 163 |
Zoloft |  | Depression and certain anxiety disorders |  | 79 |  |  | 73 |  |  | 157 |  |  | 143 |
EpiPen(a) |  | Epinephrine injection used in treatment of life-threatening allergic reactions |  | 64 |  |  | 67 |  |  | 136 |  |  | 123 |
Xalatan/Xalacom |  | Glaucoma and ocular hypertension |  | 65 |  |  | 72 |  |  | 126 |  |  | 133 |
All other Upjohn |  | Various |  | 476 |  |  | 587 |  |  | 968 |  |  | 1,109 |
CONSUMER HEALTHCARE BUSINESS(e) |  | $ | — |  |  | $ | 862 |  |  | $ | — |  |  | $ | 1,721 |
Total Alliance revenues |  |  |  | $ | 1,404 |  |  | $ | 1,187 |  |  | $ | 2,786 |  |  | $ | 2,277 |
Total Biosimilars(b) |  |  |  | $ | 289 |  |  | $ | 217 |  |  | $ | 578 |  |  | $ | 396 |
Total Sterile Injectable Pharmaceuticals(f) |  | $ | 1,237 |  |  | $ | 1,218 |  |  | $ | 2,644 |  |  | $ | 2,455 |
(a) | Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.
(b) | Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
(c) | Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
(d) | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
(e) | On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B.
(f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration